Overview

Capecitabine With Digoxin for Metastatic Breast Cancer

Status:
Terminated
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the Growth Modulation Index (GMI) of the combination of metronomic capecitabine with oral digoxin in metastatic breast cancer
Phase:
Phase 2
Details
Lead Sponsor:
Western Regional Medical Center
Treatments:
Capecitabine
Digoxin